PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells

Graphical Abstract

Highlights

- Asparaginyl endopeptidase (AEP) is expressed in induced regulatory T cells
- AEP cleaves Foxp3 and Aep−/− mice have elevated numbers of peripheral Treg cells
- AEP deficiency increases Treg cell frequency and numbers in GvHD and melanoma
- PD-1 signaling maintains Foxp3 protein expression by inhibiting AEP

Authors

Chaido Stathopoulou, Arunakumar Gangapalara, Grace Mallett, ..., Colin Watts, Ethan M. Shevach, Shoba Amarnath

Correspondence

shoba.amarnath@newcastle.ac.uk

In Brief

Th1 cells are known for their enhanced stability, so mechanisms that mediate their flexibility are poorly studied. Here, Stathopoulou et al. demonstrate that plasticity of Th1 cells to Tbet+iTreg cells is mediated by PD-1 signaling via asparaginyl endopeptidase (AEP). AEP inhibition enhanced iTreg cells in GvHD and tumor models.
CD4+ T cell differentiation into multiple T helper (Th) cell lineages is critical for optimal adaptive immune responses. This report identifies an intrinsic mechanism by which programmed death-1 receptor (PD-1) signaling imparted regulatory phenotype to Foxp3+ Th1 cells (denoted as Tbet+iTregPDL1 cells) and inducible regulatory T (iTreg) cells. Tbet+iTregPDL1 cells prevented inflammation in murine models of experimental colitis and experimental graft versus host disease (GvHD). Programmed death ligand-1 (PDL-1) binding to PD-1 imparted regulatory function to Tbet+iTregPDL1 cells and iTreg cells by specifically downregulating endolysosomal protease asparaginyl endopeptidase (AEP). AEP regulated Foxp3 stability and blocking AEP imparted regulatory function in Tbet+iTreg cells. Also, AEP−/− iTreg cells significantly inhibited GvHD and maintained Foxp3 expression. PD-1-mediated Foxp3 maintenance in Tbet+ Th1 cells occurred both in tumor infiltrating lymphocytes (TILs) and during chronic viral infection. Collectively, this report has identified an intrinsic function for PD-1 in maintaining Foxp3 through proteolytic pathway.
death ligand-1 (PDL-1 or B7-H1). In our previous work, we have found that PDL-1 can induce Foxp3 in human Th1 cells (Amaranth et al., 2011), consistent with work in murine naive T cells (Francisco et al., 2009). In the tumor microenvironment, PDL-1 expression coincides with increased intra-tumor Foxp3+ T cells (Duraiswamy et al., 2013; Jacobs et al., 2009), suggesting that PDL-1 may play a role in maintaining Foxp3 expression in CD4+ Th cell subsets. PDL-1 binds to its receptor PD-1 on T cells which signals through the inhibitory phosphatase SHP1 (Chemnitz et al., 2004). SHP1 or SHP2 recruitment results in STAT de-phosphorylation (Amaranth et al., 2011; Taylor et al., 2017), potentially destabilizing the transcriptional signature of Th1 cell lineage.

In the current study, we have elucidated an intrinsic mechanism by which PD-1 signaling maintains Foxp3 in Tbet+iTreg and iTreg cells. The data presented here demonstrate that PD-1 can inhibit a functional nuclear pool of active asparaginyl endopeptidase (AEP), an endo-lysosomal protease previously implicated in antigen processing in dendritic cells (Dall and Brandstetter, 2016; Manoury et al., 1998, 2002). We show that AEP is responsible for destabilizing Foxp3 in both iTreg and Tbet+iTreg cells. We found that PD-1 activation significantly enhanced Foxp3 expression in primed anti-viral and anti-tumor Tbet+Th1 cells, which was reversed in the presence of a blocking antibody to PDL-1. Of note, PDL-1 blockade did not reverse Tbet+Th1 cell conversion and iTreg cell induction in the absence of AEP. Therefore, this study demonstrates that downregulation of AEP is necessary for PD1-generated Foxp3 stability.

RESULTS

PD-1 Signaling, in the Absence of TGF-β1, Reinforces Foxp3 Expression in CD4+ Tbet+Foxp3+ T Cells

To investigate whether PD-1 maintains Foxp3 in Th1 cells, previously described Tbx21ZsGreen reporter mice were crossed with Foxp3ZFP mice. Flow sorted CD4+ Tbet+Foxp3+ T cells (Figures 1A, 1B, S1A, and S1B) were differentiated under iTreg cell conditions (Tbet+iTreg cells) or iTreg cell conditions with PDL-1 (Tbet+iTregPDL1 cells) (Figures 1A–1D). When subsets were maintained with interleukin-2 (IL-2) and transforming factor β (TGF-β1), Foxp3 expression under both culture conditions was similar (Figure 1D). In culture conditions where TGF-β1 was omitted from day 4 until day 7 (Figure 1E), a significant loss in Foxp3 was noted within the Tbet+iTreg cells compared with Tbet+iTregPDL1 cells (Figures 1F and 1G). We next purified Foxp3+ cells from both groups (denoted hereafter as Tbet+iTreg cells and Tbet+iTregPDL1 cells) and examined their function in vitro. Both populations suppressed effector T cell proliferation in vitro to a similar extent (Figures S1C–S1E). Tbet+iTregPDL1 cells secreted less IL-10 and IFN-γ, when compared to Tbet+Foxp3+ cells (Figure S1F). These results indicate that PDL-1 signaling maintains Foxp3 expression in Tbet+iTreg cells in the absence of TGF-β1.

PDL-1 Induces Stable Regulatory Phenotype in Tbet+iTregPDL1 Cells during Experimental Autoimmune Colitis and Graft versus Host Disease (GVHD)

The in vivo regulatory potential of Tbet+iTreg cells and Tbet+iTregPDL1 cells was next evaluated. Rag2−/− mice were reconstituted with CD4+CD45RB+CD25− naive T effector cells alone (CD45.1+) or in conjunction with various indicated flow-sorted iTreg cell populations (CD45.2+). Cohorts that received either T effector cells alone or together with Tbet+iTreg cells succumbed to colitis. By contrast, animals that received effector T cells and Tbet+iTregPDL1 cells were protected from clinical weight loss (Figure S2A). We next evaluated T effector cell function in the spleen and lamina propria lymphocytes (LPLs). Adoptive transfer of Tbet+iTregPDL1 cells significantly diminished interferon-γ (IFN-γ) production in the T effector cells in the spleen (Figures 2A and 2B) and in the LPL (Figure S2B). These results suggested that despite both groups of Th1 cells expressing Foxp3, only Tbet+iTregPDL1 cells had a robust regulatory phenotype in vivo that was comparable to iTreg cells generated from naive CD4+ cells. We next investigated whether the ability of Tbet+iTregPDL1 cells to prevent colitis was attributed to Foxp3 stability in these cells. Foxp3 expression was measured within the CD45.2+ cells isolated from the spleen (Figures 2C and 2D) and lamina propria (Figure S2C) at day 60 after adoptive transfer. Frequency of Foxp3-expressing Tbet+iTregPDL1 cells was increased when compared to cohorts that received Tbet+iTreg cells. Finally, we evaluated the inherent capacity of these cells to revert back to IFN-γ producers. We found that the capacity of Tbet+iTregPDL1 cells to secrete IFN-γ was significantly diminished when compared to Tbet+iTreg cells (Figure 2E).

The potency of Tbet+iTregPDL1 cells was then tested in an allogeneic murine GvHD model. We found that BALB/c host mice that received B6 cells stimulated under iTreg cells plus PDL-1 conditions had higher survival rates, diminished weight loss, and histological manifestations compared with mice that received cells stimulated under iTreg cell conditions alone, reaching significance in cohorts with Tbet+iTregPDL1 cells (Figures 2F, S2D, and S2E). We next measured Foxp3 expression within the CD45.2+ iTreg, iTregPDL1, Tbet+iTreg, and Tbet+iTregPDL1 cells at day 14 after transplant and found that significant Foxp3 expression was maintained within Tbet+iTregPDL1 cells (Figure 2G). We next evaluated the amount of alloreactive IFN-γ expression in the cohorts that received Tbet+iTreg and Tbet+iTregPDL1 cells. A significant reduction in the
Tbet+iTregPDL1 cell-treated cohorts (Figure 2H) was noted. These data indicate that PDL-1 induced a stable regulatory phenotype in Tbet+iTregPDL1 cells.

**PD-1 Signaling Downregulates Asparaginyl Endopeptidase in Tbet+iTregPDL1 and iTregPDL1 Cells**

In order to identify PD-1-dependent molecular mechanisms that was operational in Tbet+iTregPDL1 cells, we first evaluated AKT and mTOR signaling pathway as previously reported in iTreg cells (Francisco et al., 2009). No difference in the phosphorylation of AKT or mTOR pathway was observed (Figure S3A). Therefore, we next evaluated the gene expression profile of Tbet+iTreg and Tbet+iTregPDL1 cells. We found downregulation of a protease, namely asparaginyl endopeptidase (AEP), in Tbet+iTregPDL1 cells using micro-array analysis (Figure S3B). Consistent with our micro array data, AEP protein expression (Figure 3A) and enzyme activity was significantly decreased in Tbet+iTregPDL1 cells compared with Tbet+iTreg cells (Figures S3C and S3D). The active form of AEP was evaluated by using LE28 probe (which emits a fluorescent signal when ligated to the active form of AEP; Figure S3C; Edgington et al., 2013). We next evaluated whether a functional nuclear pool of AEP was available within Tbet+iTreg cells, as previously reported (Dall and Brandstetter, 2016; Haugen et al., 2013; Kosugi et al., 2009), using LE28 by imaging flow cytometry. We found a significant increase in the presence of active nuclear AEP in Tbet+iTreg cells compared with Tbet+iTregPDL1 cells (representative images in Figures 3B and 3C; summary of nuclear activity Figure S3E). In addition, active AEP was expressed in iTreg cells generated in the absence of PDL-1, but not in polarized Th1, Th2, CD4+CD25+ or CD4+CD25+T cells (Figures 3D and S3F). PDL-1-treated iTreg cell cultures showed relatively diminished AEP activity, which was abrogated in Pd1−/−iTreg cells (Figures 3D and S3G). Finally, we evaluated the presence of nuclear AEP by immuno blotting and confocal microscopy. In all cases, we found AEP to be expressed within the nucleus in Tbet+iTreg and iTreg cells (Figures 3E and 3F), which was limited by the addition of PDL-1 (Figure 3F).

Using confocal microscopy and imaging flow cytometry on cells stained with fluorescent pool of AEP from Foxp3 protein and active nuclear AEP, we found that Foxp3 and AEP were co-localized in Tbet+iTreg cells and iTreg cells (Figures 3G–I and S3H–S3O). This result prompted us to examine whether Foxp3 was a specific target of AEP or whether AEP indirectly regulated Foxp3 expression. Co-incubation of activated AEP with Foxp3 protein demonstrated that AEP directly cleaved Foxp3, but not T-bet protein (Figure 3J). In spite of possessing numerous asparaginyl sites, T-bet protein was refractory to AEP cleavage, whereas minimally cleaved Foxp3 bands (band 2 and 3) were noted by immuno blotting. However, band 3 was noted in conditions, which incorporated AEP inhibitor (Figures 3J). When we subjected band 2 and band 3 to high-throughput mass spectrometry, AEP-specific peptide cleavage product was found in band 2 and not band 3. Data from this analysis identified a specific semi-tryptic cleaved peptide within band 2 which was a target for AEP (N155; AEP cleaves after Asn [N]). No other AEP-specific targets were identified within the two bands (Figure 3K and Table S1).

We next evaluated Foxp3 protein turnover within Tbet+iTreg cells in the presence of AEP inhibitor. Significant inhibition of Foxp3 protein degradation was noted in the presence of AEP inhibitor in Tbet+iTreg cells (Figure S4A, top and bottom). To confirm this, we evaluated Foxp3 turnover in WT and Aep−/−iTreg cells; again, Foxp3 turnover was lower in Aep−/−iTreg cells as compared to WT iTreg cells (Figure S4B, top and bottom).

To further investigate the direct action of AEP on Foxp3, we designed a human Foxp3 mutant 1 (all N mutated to A [alanine]; 12 sites; Figures S4C and S4D). We tested whether the AEP-resistant mutant Foxp3 had enhanced stability in _in vitro_ experiments. WT and mutant 1 were transduced into HEK293T cells and then rate of Foxp3 degradation in the presence of AEP and AEP inhibitor was evaluated. AEP specifically degraded WT Foxp3 protein while showing no activity on mutated Foxp3 mutant 1 protein (Figures S4E and S4F). These _in vitro_ experiments suggest that AEP may directly act on Foxp3 protein within T cells.

**Deletion of AEP-Specific Cleavage Site in Foxp3 Results in Prevention of Alloreactive GvHD**

We next evaluated the _in vivo_ function of cells that were transduced with WT Foxp3 (mouse and human) or Foxp3 mutant 2 (human) and mouse Foxp3 mutant 1. For these experiments, we first constructed human WT and mutated Foxp3 (N154; Asn site is at 154 in human) as our mass spectrometry data were obtained from human Foxp3 protein. In addition, we also constructed WT and mutated (N153; Asn site is at 153 in mouse) mouse Foxp3. All the constructs were transduced into naive mouse T cells and Foxp3 expression was evaluated (Figure 4A, Table S1).

**Figure 2. In Vivo Function of Tbet+iTreg Cells and Tbet+iTregPDL1 Cells**

Tbet+iTreg cells and Tbet+iTregPDL1 cells were generated and then utilized for the prevention of autoimmune colitis and alloimmune GvHD. B6.Rag2−/−mice were reconstituted with CD45.1+CD45RBhiCD25+ T cells (4 × 10^5 cells/mouse) either alone or along with CD45.2+iTreg cells, iTregPDL1 cells, Tbet+iTreg cells, and Tbet+iTregPDL1 cells (1 × 10^5 cells/mouse). At day 60 after adoptive transfer, spleens were characterized. (A) Representative fluorescent plots of intracellular IFN-γ and IL-10 cytokine expression in either cohorts that received CD4+ T effector cells alone, cohorts that received Tbet+iTreg in addition to T effector cells, or cohorts that received Tbet+ITregPDL1 cells in addition to T effector cells. (B) Summary of T effector cytokine IFN-γ in the various different cohorts within CD45.1+ cell populations. (C) Representative fluorescent plots of Foxp3 expression in CD45.2+CD4+Tbet+iTreg cells and Tbet+ITregPDL1 cells. (D and E) Summary of Foxp3 and IFN-γ expression in iTreg cells, iTregPDL1 cells, Tbet+iTreg cells, and Tbet+ITregPDL1 cells. (F) Function of Tbet+iTreg cells and Tbet+ITregPDL1 cells were assessed in an experimental model of GvHD. Survival curve of mice that succumbed to GvHD in the various different cohorts. (G) Summary of Foxp3 expression in iTreg cells, iTregPDL1 cells, Tbet+iTreg cells, and Tbet+ITregPDL1 cells on day 14 after transplant. (H) Alloreactive IFN-γ was measured using Lumimex. Each experiment had n = 3–5 mice per cohorts. Data shown are cumulative from 2 independent experiments. For survival curve, each cohort consisted of n = 10 mice. Data are presented as mean ± SEM. Please also refer to Figure S2.
and nuclear localization (Figure S5A) for each construct were verified at day 4 after transduction. The transduced WT and mutant forms of Foxp3 were functional as they suppressed the capacity of the transduced cells to produce IFN-γ (IFN-γ being a specific target of Foxp3 in vitro) (Figure S5B). The in vivo suppressive function of transduced T cells was tested in a murine GvHD model (Laurence et al., 2012). We found that T cells transduced with mutated versions of Foxp3 (both mouse and human) significantly prevented GvHD lethality in murine recipients as compared to WT Foxp3 (Figure 4B).

**Inhibiting AEP Activity Maintains Foxp3 Expression in Tbet+iTreg Cells In Vivo**

We next tested the role of AEP in limiting Foxp3 stability in Tbet+iTreg cells using an AEP-specific inhibitor (AEPi). First, the in vitro efficacy of AEPi was tested in iTreg cell cultures. Naïve CD4+ CD25− T cells from WT mice were expanded under iTreg cell conditions (experimental outline in Figure 1E). Certain culture conditions were supplemented with AEPi. We found that the AEPi cultures had significantly higher Foxp3 expression as compared to the control cultures, whereas no significant difference was noted in Aep−/− iTreg cell cultures, thus confirming the specificity of the AEP inhibitor (Figures S5C and S5D). Splenic Tbet+Foxp3− Th1 cells were expanded into Tbet+iTreg cells in the presence of AEP inhibitor (MV026630, 100 μM) and then Foxp3 stability was tested in vivo. Murine recipients were reconstituted with CD4+CD25− naïve T cells (CD45.1+) along with Tbet+iTreg cells (CD45.2+) expanded in the presence of vehicle (DMSO) or AEP inhibitor (MV026630). At day 14 after transplant, the frequency of Foxp3+ cells within the adoptively transferred Tbet+iTreg cells was measured. Tbet+iTreg cells generated in the presence of AEPi exhibited an enhanced frequency of Foxp3+ cells as compared to control Tbet+iTreg cells (Figures 4C and 4D). To further evaluate the role of AEP in Tbet+iTreg cell function, we overexpressed AEP in Tbet+iTregPDL1 cells using a retro-virus. AEP overexpression and nuclear localization was first confirmed (Figures S5E and S5F) in Tbet+iTregPDL1 cells. We then tested the function of overexpressed AEP by transducing Aep−/− iTreg cells with either empty vector (EV) or AEP RV. At day 7 after expansion, Aep−/− iTreg cells were capable of expressing Foxp3, which was completely abrogated when AEP was overexpressed (Figure S5G). We then evaluated the clinical outcome of overexpressing AEP (in Tbet+iTregPDL1 cells) or inhibiting AEP (in Tbet+iTregPDL1 cells) in acute GvHD. BALB/c mice that received B6 Tbet+iTregPDL1 cells with forced expression of AEP had a significantly higher mortality compared with those that received control B6 Tbet+iTregPDL1 cells. Similarly, Tbet+iTreg cells expanded with AEP inhibitor showed similar regulatory function to that of Tbet+iTregPDL1 cells in vivo (Figure 4E). To further confirm the role of AEP in Treg cell function in vivo, a retroviral small inhibitory RNA (RV-shRNA) for AEP was utilized. AEP silencing in Tbet+iTreg cells was effective (Figures S5H–S5J). Murine recipients reconstituted with Tbet+iTreg cells transduced with AEP RV-shRNA had a significant delay in the loss of Foxp3 (Figures 4F–4H). Ablating AEP had minimal effect on the expression of Tbet in Tbet+iTreg cells (Figure 4I). Finally, we mutated the nuclear localization sequence in AEP (AEP NLS mutant) and then evaluated Foxp3 stability. We found that overexpressing AEP NLS mutant in Aep−/− iTreg cells maintained Foxp3 expression but this was not the case in cohorts that overexpressed AEP WT protein (Figures S5K–S5M).

**AEP Deficiency Modulates In Vivo Treg Cell Function by Maintaining Foxp3 Expression**

To further assess the role of AEP in Foxp3 regulation, we evaluated the efficacy of iTreg cells from Aep−/− mice in an experimental murine model of GvHD. First, we characterized the CD4+ T cell compartment within Aep−/− mice. WT and Aep−/− mice had a similar phenotype with respect to T cell frequency and activation, but Aep−/− mice had higher Treg cell frequency (Figures 5A–5F, S6A, and S6B). By contrast, no significant difference was noted in the cytokine expression by CD4+ T cells from WT and Aep−/− mice (Figure S6C). Next, in vitro expanded iTreg cells from WT and Aep−/− naïve CD4+ T cells (Figure S6D) were tested in GvHD. Aep−/− iTreg cells were significantly efficient at preventing GvHD compared to WT iTreg cells (Figure 5G). Of note, cohorts treated with Aep−/− iTreg cells (CD45.2+) had significantly higher numbers of Foxp3+ cells in the spleen and lymph nodes (Figures 5H, S6E, and S6F) as compared to WT iTreg cell-treated cohorts.

In order to explore the relationship between PD-1 signaling and AEP activation within T cells, we tested the frequency of Treg cells in Aep−/− mice under disease conditions in the presence of PDL-1 blocking antibody. A syngeneic B16F10...
Figure 4. AEP-Specific Foxp3 Mutants and AEP Inhibition Prevents GvHD

(A) Murine CD4⁺CD25⁻ T cells were transduced with WT human Foxp3, mutant (N154) human Foxp3, WT murine Foxp3, or mutant murine Foxp3 (N153). Transduction efficiency at day 4 was measured by flow cytometry.

(B) Host BALB/c mice were subjected to lethal total body irradiation (TBI; 950cGy) and then reconstituted with B6 T depleted bone marrow (BM, 5 × 10⁶ cells) alone, or with CD4⁺CD25⁻ T cells (CD45.1 marked, 0.1 × 10⁶). Certain cohorts were treated with BM plus CD4⁺CD25⁻ T plus non-transduced T cells.

(legend continued on next page)
melanoma tumor model was used whereby WT and Aep−/− mice were reconstituted with tumor cells and the cohorts were treated with either isotype or PDL-1 antibody. At day 11, tumors were resected and the tumor infiltrating lymphocytes (TILs) were tested for the frequency of Foxp3+ Treg cells and Tbet+Foxp3+ Treg cells. We found that Aep−/− cohorts had a small but significant increase in Foxp3+ TILs compared to WT cohorts (Figures 5I and 5J). In the presence of anti-PDL-1, we saw a decrease in Foxp3+ TILs in the tumors of WT cohorts but no change in the Aep−/− cohorts (Figures 5I and 5J). When we gated on Tbet+ TILs, we found a similar pattern with an elevated proportion of Tbet+ TIL’s expressing Foxp3 in the Aep−/− compared with WT mouse cohorts and the addition of anti-PDL-1 significantly inhibiting Foxp3 expression only in the WT cohorts (Figures 5K and 5L). Collectively, these in vivo experiments confirm our in vitro data and identified PD-1 as a regulator of Foxp3 through AEP.

**Tbet+ Th1 Cells Primed during Acute and Chronic Viral Infections Uregulate Foxp3 Ex Vivo**

We next investigated whether Th1 cells arising during viral infection can also be induced to express Foxp3. First, during acute LCMV infection, a significant percentage of Tbet+Foxp3+ cells was observed at day 14 after infection (Figures 6A, 6B, and S7A) and second, Tbet+Foxp3− cells had significant PD-1 expression (Figures S7B and S7C). These virus-primed CD4+ Tbet+Foxp3− cells were sorted on day 14 after infection and cultured in vitro under iTreg cell conditions with or without PDL-1. In both cases, iTreg cell-polarizing cytokines could induce Foxp3 expression in Th1 cells and this was enhanced to a small but significant extent in the presence of PD-1 (Figure 6C). Similarly, during chronic LCMV infection, a substantial increase was noted in Tbet+Foxp3+ cells at day 14 after infection in vivo (Figures 6D, 6E, and S7D) and again, Tbet+Foxp3+ cells had significant PD-1 expression (Figures S7E and S7F). These chronic LCMV virus-primed CD4+ Tbet+Foxp3+ cells were sorted on day 14 after infection and cultured in vitro under iTreg cell conditions with or without PDL-1. In both cases, iTreg cell-polarizing cytokines could induce Foxp3 expression in Th1 cells and this was enhanced by a small but significant extent in the presence of PD-1 (Figures 6F and 6G). In order to confirm that PDL-1 is required for conversion of Tbet+ cells into Tbet+pTreg cells during chronic LCMV, we adoptively transferred flow-sorted CD45.2+ Tbet+Foxp3+ cells into CD45.1+ hosts infected with chronic LCMV. Mice were treated with either isotype or anti-PDL-1 antibody. At day 10, frequency of converted Tbet+Foxp3+ in the spleen was measured (Figures 6H and 6I). Anti-PDL-1 treatment significantly inhibited the conversion of Tbet+ cells into Foxp3+ cells and enhanced the proliferation of both total and GP33 specific CD45.1+ CD8+ T cells in vivo (Figures S7G–S7M).

**Tbet+pTreg Cells Are Increased in the TILs of Mice Bearing B16F10 Melanoma Tumor**

In order to identify the biological context during which Tbet+ pTreg cells arise from Tbet+Th1 cells, an animal model of B16F10 melanoma, where PD-1-based therapies play an important role, was used. Adoptive transfer of Tbet+Th1 cells into murine recipients with established tumor was performed (outline of experimental methodology, Figure 7A). The emergence of Tbet+ pTreg cells was then evaluated in the spleen and within the TILs. A significant increase in Tbet+pTreg cells was noted within the TILs in the tumor microenvironment (Figures 7B and 7C). We next tested whether PDL-1 contributed to the differentiation of Tbet+Th1 cells into Tbet+iTreg cells in the tumor microenvironment. Stimulation with PDL-1 significantly enhanced Foxp3 expression in sorted Tbet+Th1 cells from tumor-bearing mice in ex vivo cultures (Figures 7D and 7E). We subsequently tested in vivo Tbet+ cell conversion in our tumor model. Rag2−/− mice were reconstituted with tumor cells followed by adoptive transfer of sorted Tbet+Foxp3+ cells. Cohorts were treated with either isotype control or anti-PDL-1 and then TILs were evaluated for Tbet+Foxp3+ cells. The frequency of Tbet+pTreg cells was significantly increased in the isotype-treated cohorts but not in the anti-PDL-1-treated murine recipients (Figures 7F–7H). The experiment was repeated with Tbet+Foxp3− cells that were transduced with either control shRNA RV or AEP shRNA RV. Consistent with our experiments performed using Aep−/− mice, AEP silencing rendered Tbet+ cells refractory to PDL-1 blockade and resulted in significant conversion toward Tbet+ Foxp3+ cells within the tumor microenvironment (Figures 7I and 7J). Finally, we evaluated conversion of CD45.2+ Tbet+ cells in CD45.1+ hosts that were reconstituted with B16F10 melanoma tumor. Certain cohorts were treated with both isotype or anti-PDL-1 antibody. In this experimental condition, we again found that Tbet+Foxp3− cells were capable of converting to Tbet+iTreg cells within the tumor microenvironment, which was efficiently blocked in the presence of PDL-1 antibody (Figures 7K and 7L). In all these experiments, CCR4 expression on Tbet+ Foxp3+ cells within the tumor microenvironment was minimal (data not shown). These results suggest that Tbet+ cell conversion can occur in vivo within the tumor microenvironment and...
PDL-1 blockade reverses the conversion of Tbet+ cells into Tbet+Foxp3+ cells. However, anti-PDL-1 effect in blocking Tbet+ cell conversion to Tbet+Foxp3+ cells is abrogated in the absence of AEP.

**DISCUSSION**

The regulation of Foxp3 in Treg cells and T helper cell subsets is an active area of investigation and may help in understanding dysregulation of the immune system in disease processes. In this report, we have identified a proteolytic regulation of Foxp3 protein in iTreg cells, Tbet+iTreg cells, and pTbet+iTreg cells. We demonstrated that (1) PD-1 signaling maintains Foxp3 protein stability through regulating AEP, (2) AEP directly cleaves Foxp3 and results in Foxp3 instability in iTreg cells and Tbet+iTreg cells, and (3) inhibiting AEP resulted in enhanced Treg cell function. These data elucidate a basic mechanism that is operational in Treg cells and paves a path to the development of translational approaches for developing Treg cell-based cell therapies.

The results outlined in this paper are in agreement with the existence of these Tbet+Foxp3+ T cells in vivo. However, reports on Tbet+Treg cells (Hall et al., 2012; Koch et al., 2009, 2012; Levine et al., 2017) propose that iTreg cells are the likely precursors of Tbet+iTreg cells. The data presented here extend these observations and clearly demonstrate that an alternate pathway is involved in the upregulation of Foxp3 expression by Tbet+Foxp3+ T cells.

In vivo cell tracing experiments performed in the long-term colitis model highlights a mechanism by which PDL-1 imparts regulatory function to Tbet+iTregPDL-1 cells. During colitis, Tbet+iTregPDL-1 cells had sustained Foxp3 expression after 60 days in an inflammatory environment unlike their counterpart Tbet+iTreg cells. These data support a regulatory mechanism whereby differentiation of Tbet+ cells in the presence of PDL-1 can result in sustained Foxp3 expression in vivo and led us to explore the molecular mechanisms by which PD-1 signaling regulated Foxp3 stability. We found a proteolytic pathway that was operational in maintaining Foxp3 protein stability in iTreg cells and Tbet+iTreg cells involving direct inhibition of the activity of AEP. PD-1 inhibition of AEP was independent of CD28 and results of Foxp3 expression (Hui et al., 2017; Kamphorst et al., 2017).

The notion that a specific protease can perform an essential specific proteolytic function is controversial as cells express many proteases that exhibit considerable functional redundancy (van Kasteren and Overkleeft, 2014). However, cell type-specific differences in protease function have been previously reported. For example, AEP breaks down self-antigens in DCs (Manoury et al., 2002) and cathepsin G performs this function in B cells (Burster et al., 2004). AEP activity has been reported both in lysosomes and in the nucleus of tumor cells (Haugen et al., 2013). Functionally AEP can induce tumor cell proliferation and migration and process antigens for optimal presentation by DCs (Andrade et al., 2011; Lin et al., 2014; Manoury et al., 1998). In contrast to other lysosomal proteases, AEP is expressed in the cytosol and nucleus and the activity of AEP across both neutral and acidic pH has been previously reported (Haugen et al., 2013). These observations enable a mechanism by which Foxp3 in the nucleus can be targeted by AEP.

The imaging and biochemical data presented here demonstrated that in T cells, AEP played a specific function in cleaving Foxp3 but not Tbet. These results are in accordance with previous AEP studies where it has been shown that AEP substrates in part are not amenable to other protease activity. In addition, AEP is well known for its substrate and cleavage specificity and often AEP-mediated cleavage results in a functional immunological outcome in vivo (Manoury et al., 1998, 2002). In T cells, AEP adheres to this phenotype, whereby it specifically targets and cleaves Foxp3 at a single site, which results in the instability of the protein. Therefore, our study implicates the occurrence of a proteolytic-mediated regulation of Foxp3 in iTreg and Tbet+iTreg cells.

The data presented here postulate a post-translational mechanism of Foxp3 protein regulation in addition to the previously described proteosomal pathway that is operational in Foxp3 regulation. However, deleting AEP was sufficient for maintaining Foxp3 protein in iTreg and Tbet+iTreg cells in vivo. In contrast to the proteosomal degradation study where an shRNA approach was used (Chen et al., 2013; van Loosdregt et al., 2013; Zhao et al., 2015), we have utilized a genetic loss-of-function model (Aep−/− mice) to demonstrate the stability of Foxp3 in vivo during acute inflammation. Furthermore, mutating AEP-specific sites in Foxp3 protected mice from GvHD-mediated lethality. Therefore, our data demonstrate that either AEP deficiency or Foxp3 mutated at AEP-specific sites can enhance Treg cell function and is a primary pathway in modulating post-translational stability of Foxp3 protein.
Our results suggest that AEP inhibitor can be used to generate large-scale Treg cells that are stable and are functionally robust in vivo. The use of PDL-1 to grow Tbet+iTreg cells may be efficacious but a substantial decrease in cell numbers can occur given the role of PD-1 in inhibiting T cell proliferation. Using AEP inhibitors, this hurdle can be overcome in order to generate large numbers of antigen-primed Tbet+iTreg cells that maintain regulatory function in vivo. In addition, donor-derived AEP-deficient Treg cells can also be generated for the treatment of GvHD.

Data from the acute and chronic LCMV-infected mice further identified a role for PDL-1 in inducing Foxp3 in primed “anti-gen-specific” Tbet+ Th1 cells. Although insufficient cell numbers prevented us from isolating antigen-specific T cells prior to ex vivo iTreg cell culture, the results presented here imply that PDL-1 can be used to generate iTreg cells from previously antigen-primed Tbet+Th1 cells. Consistent with previous studies (Hall et al., 2012; Koch et al., 2009, 2012; Levine et al., 2017), we have also identified a unique population of Tbet+iTreg cells that expands in both acute and chronic LCMV. In summary, these experiments highlight many aspects of Tbet+iTreg cells: (1) primed CD44+Tbet+Foxp3+ cells can arise during acute and chronic LCMV infection, (2) primed CD4+CD44+Tbet+Foxp3− T cells can give rise to Tbet+Foxp3+ T cells in ex vivo cultures, and finally (3) blocking PDL-1 in vivo dampened Tbet+pTreg cell conversion, therefore confirming PDL-1 as a critical mediator of Tbet+pTreg cell generation in chronic viral infection.

In melanoma, Treg cell-mediated tolerance has largely been attributed to the migration of Treg cells from the periphery to the tumor site (Spranger et al., 2013), while Tbet+ Th1 cell conversion is largely unexplored. Since the microenvironment in melanoma provides an abundance of PDL-1 that can result in activation of PD-1 signaling on Tbet+ TILs, we explored and found that Tbet+Th1 cell conversion indeed occurred. However, this study does not address the contribution of hematopoietic versus non-hematopoietic versus tumor tissue-derived PDL-1 in inducing Treg cell conversion within the tumor microenvironment. The results presented here raise the possibility that the PDL-1-driven Treg cell generation within the TILs is dependent on AEP expression and that individuals who overexpress AEP within their Treg TIL populations may be more responsive to PD-1- and/or PDL-1-based immunotherapeutics.

In conclusion, this report has identified a mechanism by which sustained PD-1 signaling induces robust regulatory function in iTreg cells through post-translational regulation of the Foxp3 protein. Therefore, this study demonstrates an insightful interaction between co-inhibitory receptor signaling and protease activity and has elucidated the importance of these two signaling pathways in maintaining T regulatory phenotype.

STAR*METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCE TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mice
- METHOD DETAILS
  - Cell sorting and Flow cytometry and tetramer staining
  - In vitro cell culture
  - In vitro Treg suppression assay
  - In vivo animal models
  - Histological Analysis
  - Affymetrix Gene Expression Profiling
  - Immuno Blotting
  - AEP enzyme activity
  - Foxp3 co-localization Assays
  - Amnis Imaging Flow cytometry
  - Foxp3 cleavage and Mass Spectrometry
  - Pulse Chase Assays for Foxp3 protein turnover
  - AEP and Foxp3 silencing and mutation assays
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND SOFTWARE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and one table and can be found with this article online at https://doi.org/10.1016/j.immuni.2018.05.006.

ACKNOWLEDGMENTS

We would like to thank Dr. Tsung-Ping and Dr. Shang-Yi Tsai, National Institute on Drug Abuse, NIH for sharing protocols on pulse chase experiments and...
analysis. We would like to thank Dr. William G. Telford for his valuable input on Amnis flow cytometry experiments and analysis. We would like to thank Dr. Billur Akkaya, NIAID, for providing us with B6. Tbx21ZsGreenFoxp3RFP mice for chronic LCMV experiments. We would like to thank Dr. Bishop Hague. NIAID, for his assistance in flow cytometry sorting of virus-infected cells. We would like to thank the core facilities at Newcastle University namely Bioimaging, Comparative Biology Centre, and Flow cytometry. We would also like to thank Mr. Christopher Huggins for his technical expertise. The authors would also like to thank the NIH tetramer core facility for providing the tetra-
mers used in this study. This research was funded by the Division of intramural research program of the NCI and NIAID, NIH, USA. Newcastle University Research Fellowship, Newcastle University, MRC-Newcastle University Single Cell Unit Award and the Academy of Medical Sciences, Springboard Award SBF0031129; G.M. is supported by MRC-DIMEN Doctoral Training Partner-
ship program; J.M.-F. and C.W. are supported by the Wellcome Trust, S.I.v.K. is supported by an ERC starter grant ER-StG-639005, and A.L. is sup-
ported by Crohn’s and Colitis Foundation of America.

AUTHOR CONTRIBUTIONS

C.S., G.M., and L.P.L. performed experiments and analyzed data; A.G. per-
formed LCMV experiments, analyzed data, and wrote the paper; D.K. provided intellec-
tual input and performed mass-spectrometry experiments; F.A.F. pro-
vided intellectual input, performed gene silencing assays, analyzed data, and wrote the paper; L.A.S. provided intellectual input, performed Amnis experi-
ments, analyzed data, and wrote the paper; T.C.F. and J.M.-F. performed ex-
periments and analyzed data; R.B.-P. provided intellectual input, performed confocal experiments, and analyzed data; L.E.-M. and J.J.Y. engineered LE28 probe; M.A.E. scored histology; M.B., C.W., and S.I.v.K. provided intel-
lectual input on AEIP experiments, provided relevant AEIP reagents, critically read, and wrote manuscript; E.M.S., A.L., D.H.F., and J.Z. provided intellectual input and reagents and critically read and wrote manuscript; and S.A. concep-
tualized the project, designed experiments, provided intellectual input, analyzed data, and wrote paper.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: February 23, 2017
Revised: April 30, 2018
Accepted: May 17, 2018
Published: July 24, 2018

REFERENCES

Adeeku, E., Gudapati, P., Mendez-Fernandez, Y., Van Kaer, L., and Boothby, M. (2008), Flexibility accompanies commitment of memory CD4 lymphocytes
9307–9312.

Figure 7. Tbet+Th1 Cells Uregulate Foxp3 in Tumor Microenvironment

(A) B6.Rag2−/− mice were subcutaneously injected with B16F10 melanoma cells. At day 7 after tumor inoculation, adoptive transfer of Tbet+ Th1 cells was
performed.

(B) Mice were euthanized on day 14, splenocytes and TILs were isolated, and then Tbet+Foxp3+ cell frequency was determined.

(C) Summary of Foxp3+ Tbet+ cells from the spleen and TIL. (D and E) Tbet+Foxp3− cells were flow sorted from the spleen and then expanded under iTreg cell conditions or iTreg cell conditions plus PDL-1Fc. The upre-
gulation of Foxp3 was then monitored by flow cytometry at day 7 post culture.

(F–H) B6.Rag2−/− mice were subcutaneously injected with B16F10 melanoma cells and adoptive transfer of Tbet+ Th1 cells was performed at day 5. Cohorts were
either treated with isotype control or anti-PDL-1 antibody (250 µg/mouse) at days 5, 7, and 9. Animals were euthanized at day 11. Experimental methodology
outlined in (F), and the frequency of Tbet+iTreg cells was monitored within the TILs (G and H).

(I and J) Experiments were performed with Tbet+Foxp3− cells transduced with either scramble shRNA RV or AEP shRNA RV and then treated with anti-PDL-1
antibody. Frequency of Tbet+iTreg cells within the TILs in the different cohorts.

(K and L) Murine CD45.1+ hosts were reconstituted with B16F10 melanoma tumors and sorted CD45.2+ Tbet+Foxp3+ cells. Cohorts were treated with either
isotype or anti-PDL-1 antibody. Frequency of Tbet+iTreg cells was measured within the TILs.

Experiments were repeated at least twice and data are shown as mean ± SEM from one to two individual experiments involving n = 3–8 mice per group.


# STAR METHODS

## KEY RESOURCE TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 (RM4-4)</td>
<td>BioLegend</td>
<td>Cat#116011</td>
</tr>
<tr>
<td>CD8 (53-6.7)</td>
<td>BioLegend</td>
<td>Cat#100759</td>
</tr>
<tr>
<td>CXCR3 (CXCR3-173)</td>
<td>BioLegend</td>
<td>Cat#126521</td>
</tr>
<tr>
<td>PDL-1 (10F.9G2)</td>
<td>BioLegend</td>
<td>Cat#124319</td>
</tr>
<tr>
<td>CD44 (IM7)</td>
<td>BD Biosciences</td>
<td>Cat#553134</td>
</tr>
<tr>
<td>CD45.1 (A20)</td>
<td>BD Biosciences</td>
<td>Cat#565813</td>
</tr>
<tr>
<td>CD45.2 (104)</td>
<td>BD Biosciences</td>
<td>Cat#740490</td>
</tr>
<tr>
<td>CD45RB (C363.16A)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#17-0455-81</td>
</tr>
<tr>
<td>PD-1 (29F.1A12)</td>
<td>BioLegend</td>
<td>Cat#135219</td>
</tr>
<tr>
<td>H-2K{	extsuperscript{b}} (AF6-88.5)</td>
<td>BD Biosciences</td>
<td>Cat#562832</td>
</tr>
<tr>
<td>CD62L (MEL-14)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#15-0621-81</td>
</tr>
<tr>
<td>CD8 (53-6.7)</td>
<td>BioLegend</td>
<td>Cat#100737</td>
</tr>
<tr>
<td>CCR4 (2G12)</td>
<td>BioLegend</td>
<td>Cat#131217</td>
</tr>
<tr>
<td>Neuropilin-1 (3E12)</td>
<td>BioLegend</td>
<td>Cat#145207</td>
</tr>
<tr>
<td>Helios (22F6)</td>
<td>BioLegend</td>
<td>Cat#137229</td>
</tr>
<tr>
<td>CD25 (PC61)</td>
<td>BioLegend</td>
<td>Cat#102035</td>
</tr>
<tr>
<td>CD127 (A7R34)</td>
<td>BioLegend</td>
<td>Cat#135035</td>
</tr>
<tr>
<td>LAMP-1 (1D4B)</td>
<td>BioLegend</td>
<td>Cat#121616</td>
</tr>
<tr>
<td>Foxp3 (FJK-16 s)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#12-5773-82</td>
</tr>
<tr>
<td>IL-10 (1E6-16E3)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#17-7101-81</td>
</tr>
<tr>
<td>IFN-{	extgamma} (XMG1.2)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#25-7311-41</td>
</tr>
<tr>
<td>K67 (SolA15)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#25-5698-82</td>
</tr>
<tr>
<td>Anti-CD3 (145-2C11)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#16-0031-82</td>
</tr>
<tr>
<td>Anti-CD28 (37.51)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#16-0281-82</td>
</tr>
<tr>
<td>LEAF Purified anti-mouse IL-4 (11B11)</td>
<td>BioLegend</td>
<td>Cat#504115</td>
</tr>
<tr>
<td>LEAF Purified anti-mouse IFN-{	extgamma} (XMG1.2)</td>
<td>BioLegend</td>
<td>Cat#505827</td>
</tr>
<tr>
<td>Anti-mouse PDL-1 (10F.9G2)</td>
<td>Bio X Cell</td>
<td>Cat#BP0101</td>
</tr>
<tr>
<td>Rat-IgG2b Isotype Control (LTF-2)</td>
<td>Bio X Cell</td>
<td>Cat#BP0090</td>
</tr>
<tr>
<td>Mouse Legumain</td>
<td>R&amp;D Systems</td>
<td>Cat#MAB2058</td>
</tr>
<tr>
<td>PTEN</td>
<td>Cell Signal</td>
<td>Cat#9188</td>
</tr>
<tr>
<td>mTOR</td>
<td>Cell Signal</td>
<td>Cat#2972</td>
</tr>
<tr>
<td>Phospho-mTOR</td>
<td>Cell Signal</td>
<td>Cat#2971</td>
</tr>
<tr>
<td>AKT</td>
<td>Cell Signal</td>
<td>Cat#4691</td>
</tr>
<tr>
<td>Phospho-AKT ser473</td>
<td>Cell Signal</td>
<td>Cat#4060</td>
</tr>
<tr>
<td>Phospho-AKT Thr308</td>
<td>Cell Signal</td>
<td>Cat#2965</td>
</tr>
<tr>
<td>Foxp3</td>
<td>Cell Signal</td>
<td>Cat#12653</td>
</tr>
<tr>
<td>P70S6K</td>
<td>Cell Signal</td>
<td>Cat#2708</td>
</tr>
<tr>
<td>Phospho P70S6K (Thr421/Ser424)</td>
<td>Cell Signal</td>
<td>Cat#9204</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>Cell Signal</td>
<td>Cat#9102</td>
</tr>
<tr>
<td>Phospho-ERK</td>
<td>Cell Signal</td>
<td>Cat#9101</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Cell Signal</td>
<td>Cat#5174</td>
</tr>
<tr>
<td>α-tubulin</td>
<td>Cell Signal</td>
<td>Cat#5346</td>
</tr>
<tr>
<td>α-actin</td>
<td>Cell Signal</td>
<td>Cat#4967</td>
</tr>
<tr>
<td>Lamin B1</td>
<td>Cell Signal</td>
<td>Cat#13435</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit IgG HRP</td>
<td>Cell Signal</td>
</tr>
<tr>
<td>Rat IgG HRP</td>
<td>R&amp;D systems</td>
</tr>
</tbody>
</table>

### Bacterial and Virus Strains

<table>
<thead>
<tr>
<th>Strain</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armstrong Strain</td>
<td>LCMV Dr. Ethan Shevach Laboratory, NIH, USA</td>
</tr>
<tr>
<td>Clone-13 Strain</td>
<td>LCMV Dr. Ethan Shevach Laboratory, NIH, USA</td>
</tr>
</tbody>
</table>

### Chemicals, Peptides, and Recombinant Proteins

<table>
<thead>
<tr>
<th>Chemical/Protein</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDL-1 Fc Chimera</td>
<td>R&amp;D Systems</td>
</tr>
<tr>
<td>AEP inhibitor MV026630</td>
<td>Prof. Colin Watts, Dundee, UK</td>
</tr>
<tr>
<td>AEP protein</td>
<td>Prof. Colin Watts, Dundee, UK</td>
</tr>
<tr>
<td>AEP Cy5 probe</td>
<td>Edgington et al.</td>
</tr>
<tr>
<td>rmTGF-β1</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Cycloheximide</td>
<td>Edgington et al.</td>
</tr>
<tr>
<td>Leupeptin</td>
<td>Sigma-Aldrich</td>
</tr>
<tr>
<td>Foexp3 protein</td>
<td>Origene</td>
</tr>
<tr>
<td>Tbet protein</td>
<td>Origene</td>
</tr>
<tr>
<td>DAPI</td>
<td>BioLegend</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foxp3 Transcription Factor Staining Buffer Kit</td>
<td>Thermo Fisher Scientific</td>
</tr>
<tr>
<td>CD90.2 microbeads</td>
<td>Miltenyi Biotec</td>
</tr>
<tr>
<td>Mouse Regulatory T cell isolation kit</td>
<td>Miltenyi Biotec</td>
</tr>
<tr>
<td>CellTrace Violet Cell Proliferation Kit</td>
<td>Thermo Fisher Scientific</td>
</tr>
</tbody>
</table>

### Deposited Data

<table>
<thead>
<tr>
<th>Type</th>
<th>Accession</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microarray</td>
<td>GEO:GSE113815</td>
</tr>
</tbody>
</table>

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH 3T3</td>
<td>Dr. Francis Flomerfelt, NCI, NIH</td>
</tr>
<tr>
<td>293T</td>
<td>Dr. Francis Flomerfelt, NCI, NIH</td>
</tr>
<tr>
<td>B16F10 melanoma</td>
<td>Dr. Pawel Muranski and Dr. Nick Restifo, NCI, NIH</td>
</tr>
</tbody>
</table>

### Experimental Models: Organisms/Strains

<table>
<thead>
<tr>
<th>Strain</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57BL/6</td>
<td>Charles River</td>
</tr>
<tr>
<td>BALB/c</td>
<td>Charles River</td>
</tr>
<tr>
<td>C57BL/6 Rag2−/−</td>
<td>Jax Mice</td>
</tr>
<tr>
<td>C57BL/6 Foxp3RFP</td>
<td>Jax Mice</td>
</tr>
<tr>
<td>C57BL/6 CD45.1</td>
<td>Jax Mice</td>
</tr>
<tr>
<td>C57BL/6 TbetZsgreen</td>
<td>Dr. Jinfang Zhu, NIH, USA</td>
</tr>
<tr>
<td>C57BL6 PDCD1−/−</td>
<td>Prof. Tasuku Honjo, Japan</td>
</tr>
<tr>
<td>C57BL/6 AEP−/−</td>
<td>Prof. Colin Watts, Dundee, UK</td>
</tr>
</tbody>
</table>

### Oligonucleotides

<table>
<thead>
<tr>
<th>Oligonucleotide</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legumain (AEP) Mouse ShRNA</td>
<td>Origene</td>
</tr>
<tr>
<td>Scramble Mouse ShRNA</td>
<td>Origene</td>
</tr>
</tbody>
</table>

### Recombinant DNA

<table>
<thead>
<tr>
<th>Oligonucleotide</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>AEP cDNA</td>
<td>Prof. Colin Watts</td>
</tr>
</tbody>
</table>

*(Continued on next page)*
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact, Dr. Shoba Amarnath (shoba.amarnath@newcastle.ac.uk).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice
Female C57BL/6 (B6, H-2Kb) and BALB/c (H-2Kd) mice 8- to 10- weeks old were obtained from Frederick Cancer Research Facility, USA or Charles River, UK. Female C57BL/6 Rag2−/− and C57BL/6 Foxp3RFP mice were purchased from Jackson Laboratories, Aep−/− and WT littermate controls were kindly provided by C. Watts. B6.Foxp3RFP mice in a specific pathogen-free facility at the National Institutes of Health, USA and at Newcastle University, UK. B6.Tbx21ZsGreenFoxp3RFP mice were utilized for all T cell lineage-tracing experiments. The use of animals for this research was approved by the Animal Care and Use Committee, National Cancer Institute, and National Institute of Allergy and Infectious Diseases, NIH, and carried out in accordance with the NIH animal health and safety guidelines. Animal experiments conducted at Newcastle University were approved by the Newcastle Ethical Review committee and performed under a UK home office approved project license. Experimental methodology was in accordance to the NC3R recommendations and data are shown in accordance with ARRIVE guidelines.

METHOD DETAILS

Cell sorting and Flow cytometry and tetramer staining
Unless stated otherwise, ZsGreen fluorescence was used to determine Tbet expression and RFP fluorescence was used to sort various cell populations. CD4+Tbet+Foxp3+ Th cells were characterized by multi-parameter flow cytometry for surface markers. Cytokine phenotype of day 0 cells was measured by stimulating cells with phorbol-12-myristate 13-acetate (PMA) and ionomycin for four hours along with Golgiplug and Golgistop which was added in the last 2 hr of incubation. Flow cytometry staining antibodies for CD4 (clone: RM4-4), CXCR3 (clone: CXCR3-173), PD-1 (clone: 29F.1A12), PDL-1 (clone: 10F.9G2), CD44 (clone: IM7), CD45.1 (clone: A20), CD45.2 (clone: 104), H-2Kb (AF6-88.5), CD62L (clone: MEL-14), CD8 (clone: 53-6.7), CCR4 (clone: 2G12), Neuropilin-1 (clone: 3E12), Helios (clone: 22F6), CD25 (clone: PC61) and CD127 (clone: A7R34) were purchased from BioLegend. Foxp3 (clone: FJK-16 s), IL-10 (clone: JES5-16E3), IFN-γ (clone: XMG1.2) and Ki67 (clone: SolA15) were from Thermo Fisher Scientific. For MHC class I tetramer staining, H-2Db GP33-41 was used at 1:100 dilutions and staining was performed at 4°C for 1 hr. Data were acquired using either an LSR II or Fortessa or FACS CANTO and analyzed using FlowJo software version 9.6.4 or 10.0.6.

In vitro cell culture
CD4+Tbet+Foxp3+ T helper cells were flow sorted and stimulated in 24 well cell culture plates coated with anti-CD3 (clone:145-2C11; 5 µg/ml) for 3 days in cell culture media [RPMI, supplemented with 10% FCS, glutamine (2 mM), non-essential amino acids (0.1 mM), 2-mercaptoethanol (50 µM), sodium pyruvate (1 mM), penicillin and streptomycin (100 IU/ml)] along with soluble anti-CD28 (clone:37.51:2 µg/ml), mIL-2 (80 ng/ml), rhTGF-β1 (2 ng/ml), anti-IL-4 (BioLegend, clone:11B11; 20 µg/ml) and anti-IFN-γ (BioLegend, clone: XMG1.2; 20 µg/ml) with or without coated PDL-1fc chimera (5 µg/ml). After 3 days of culture, cells were expanded for an additional four days in the presence of IL-2 (80 ng/ml) and TGF-β1 (2 ng/ml) or with IL-2 alone. Cells were then characterized by intracellular flow cytometry for Foxp3 expression. Both populations were flow sorted for Foxp3+ cells and are denoted as Tbet+iTreg and Tbet+iTregPDL1 cells. Post-differentiation Tbet+iTreg and Tbet+iTregPDL1 cells were stimulated overnight with anti-CD3 and anti-CD28 and then supernatants were subjected to a multiplex bead array luminess assay. Control populations of iTregs (iTreg and iTregPDL1) were generated from CD4+Tbet-Foxp3- subsets, which were similarly cultured and characterized. Subsequently, expanded Foxp3+ cells from the various subsets were sorted and utilized in in vitro suppression assays and in vivo animal models of autoimmunity and allograft immunity. In certain experiments, CD4+Tbet+Foxp3+ T helper cells were either cultured with AEP inhibitor MV026630 (100 µM) or AEP ShRNA or Vehicle (DMSO) from day 0 of culture in addition to anti-CD3, anti-CD28, rh-IL-2 and rh-TGF-β1 prior to being used as cellular therapeutics.
*In vitro* Treg suppression assay

CD4+CD25+ cells were isolated using the Miltenyi Biotec Treg isolation kit and utilized in a Treg suppression assay as previously described (Thornton and Shevach, 1998). Purified CD4+CD25+ cells (5x10⁵) were labeled with CellTrace Violet and then cultured in 96 well round bottom plates in 200 μL complete media along with 2x10⁵ irradiated T cell-depleted spleen cells (3000 cGy) as accessory cells. Anti-CD3 (0.5 μg/ml) was added along with cultured flow sorted Foxp3+ iTreg populations (iTreg, iTregPDL1, Tbet+ iTreg and Tbet+ iTregPDL1) cells at the indicated ratios. Cells were incubated at 37 °C for 72 hr and proliferation and suppression was monitored by flow cytometry. Proliferation of responder T cells was evaluated by CellTrace Violet dilution. Percent suppression of CD4 responder T cell was calculated with values representing the ratio of total divided peaks to both divided and non-divided peaks, normalized to the anti-CD3 alone experimental group.

*In vivo* animal models

**Experimental Autoimmune Colitis**

B6.Rag2−/− female mice were reconstituted with B6. CD45.1+CD4+CD25+CD45RBhi (T effectors) populations (4x10⁵) as previously described (Asseman et al., 1999) along with flow sorted B6.CD45.2+ iTreg cells (1x10⁵), iTregPDL1 cells (1x10⁵), Tbet+ iTreg (1x10⁵), or Tbet+ iTregPDL1 cells (1x10⁵). Mice were weighed weekly and loss of body weight was used as an indicator of colitis. Immune endpoints were measured in the splenocytes and in LPL. LPL were isolated as previously described (Asseman et al., 1999). Briefly, large intestine was digested using Liberase TL and DNase I followed by percoll gradient centrifugation. LPLs were washed twice with complete media and then used for immunological assays. Both splenocytes and LPL were stimulated with PMA and ionomycin along with GolgiPlug and Golgistop for 4 hr and then effector cytokines were measured by intracellular flow cytometry.

**Experimental Allogeneic GVHD**

BM was flushed from B6 donor femurs and tibias and T cell depleted (TDBM) using CD90.2 MACS beads (Miltenyi Biotec). Host alloreactive (BALB/c) female mice were conditioned with total body irradiation of 950 cGy in two divided doses three hours apart before being rescued with 10⁷ TDBM cells together with 1x10⁶ CD4+CD25+ T cells from WT CD45.1+ B6 donors. In addition, various flow sorted iTreg populations (CD45.2+; 1x10⁵) were adoptively transferred for prevention of GVHD. Survival was monitored as a measure of Treg cell potency. Alloreactive IFN-γ was measured as follows: Single cell suspension of splenocytes (1x10⁶) was cultured over-night with either syngeneic or allogeneic bone marrow derived dendritic cells DCs (1x 10⁵). Supernatant was harvested at 24 hr and Th1 cytokines were measured by using a multiplex lumineux bead array system. Allogenic IFN-γ cytokine in the supernatant was measured by subtracting the amount of IFN-γ present in the syngeneic controls.

**LCMV**

Six to eight weeks old B6.Tbx21ZsGreenFoxp3RFP mice were infected with Armstrong (2x10⁵ PFU, i.p) or Clone-13 virus (2x10⁶ PFU, i.v) as previously described (Wherry et al., 2003). Titers of virus were determined by plaque assay on Vero cells as previously described (Ahmed et al., 1984). At indicated time points, spleens were harvested and the frequency of Tbet+ Foxp3+ T cells was characterized by flow cytometry. In certain experiments, primed CD4+ Tbet+Foxp3+ cells were transfected with or without PDL-1 followed by Foxp3 characterization using flow cytometry. B6.CD45.1+ murine recipients were injected with anti-CD4 (500 μg/mouse; day −7) infected with Clone-13 virus along with adoptive transfer of CD45.2+ Tbet+Foxp3+ cells (0.7x10⁶). Cohorts were treated with either isotype or anti-PDL-1 antibody (200 μg/mouse) at day 1, 5 and 9. On day 10 Tbet+ Foxp3+ cells were analyzed in spleens of the infected mice.

**B16F10 melanoma**

B6.Rag2−/− mice, WT mice, CD45.1 and Aep−/− mice were reconstituted with 3x10⁵ B16F10 melanoma cells (kindly provided by Dr. Pawel Muranski and Prof. Nick Restifo, NCI,NIH) and the tumor was allowed to progress for 7 days. At day 7, murine recipients were reconstituted with 2x10⁵ Tbet+Foxp3+ T effectors from B6.Tbx21ZsGreenFoxp3RFP mice. At day 14 post-tumor inoculation, mice were euthanized, spleen and TILs were isolated and analyzed for the presence of Tbet+Foxp3+ cells. In certain experiments, cohorts were treated with either isotype or anti-PDL-1 antibody (250 μg/mouse) at days 5, 7 and 9. For shRNA experiments, Rag2−/− mice were reconstituted with tumor at day 0 along with flow sorted CD44+Tbet+Foxp3+ T cells transduced with either scramble or AEP shRNA. Murine recipients were then treated with anti-PDL-1 antibody at days 5, 7 and 9. Host CD45.1+ murine hosts were reconstituted with tumor at day 0 along with flow sorted CD4+Tbet+Foxp3+ T cells and then treated with antibodies at days 5, 7 and 9. Splenocytes and tumors were harvested at day 11 and the frequencies of Foxp3+ cells were evaluated.

**Histological Analysis**

Representative samples of liver, intestine and colon were obtained from the mice that underwent GVHD and fixed in 10% phosphate buffered formalin. Samples were embedded in paraffin, sectioned and stained with hematoxylin and eosin. All slides were coded and read by an external pathologist (Dr. Michael Eckhaus) in a blinded fashion. A four-point scale of GvHD severity was used to score the samples.

**Affymetrix Gene Expression Profiling**

Total RNA was isolated with RNaseasy kit from QIAGEN. RNA quality was checked on Agilent Bioanalyzer. All samples used for micro-array analysis had high quality score (RIN > 9). 100 mg of RNA was reverse transcribed and amplified using Ambion WT expression kit following manufacturer’s suggested protocol. Sense strand cDNA was fragmented and labeled using Affymetrix WT terminal labeling kit. Four replicates of each group were hybridized to Affymetrix mouse Gene ST 2.0 GeneChip in Affymetrix hybridization oven at
AEP enzyme activity

Protein lysates were obtained from Tbet+ iTreg and Tbet+ iTregPDL1 cells. Lysates were run on 10%–20% SDS-PAGE gels and transferred onto nitrocellulose membrane. Membranes were blocked with 5% milk in TBST buffer (20mmol/L TrisHCl, 500 mmol/L NaCl, and 0.01% Tween-20) and incubated overnight at 4 °C with primary antibodies (Ab) in TBST containing either 5% milk or BSA. Immune reactivity was detected by sequential incubation with HRP-conjugated secondary Ab and enzymatic chemiluminescence (Cell Signaling Technology). Primary Abs to mouse PTEN, mTOR, phospho-mTOR, Akt, phospho-AKT (Ser473 and Thr 308), Foxp3, P70S6K, phospho-p70S6K, ERK, phospho-ERK, GAPDH, β-tubulin, β-actin were procured from Cell Signaling. AEP (Legumain) was obtained from R&D systems. Images were acquired using a LiCOR FcOdyssey system or Wes Simple Protein system.

Foxp3 co-localization Assays

The co-localization of Foxp3 in the nucleus was measured using imaging flow cytometry on the Amnis Image Stream MKII. For this, cells were fixed and then stained with DAPI, Foxp3 APC and LAMP-1 APC-Cy7 (BioLegend, clone 1D4B). For co-localization experiments with AEP cells were stained with DAPI, Foxp3 PE, LAMP-1 APC-Cy7; and LE28 Cy5.

Amnis Imaging Flow cytometry

Sample Acquisition: Samples were run on an Image StreamX MKII using INSPIRE data acquisition software (Amnis EMD-Millipore) at a concentration of approximately 1×10^6 cells in 50 μL of PBS. The system was outfitted with 2 cameras, 12 channels, 405, 488, 561, 642, and 785nm lasers, and an extended depth of field element (EDF). Brightfield was collected in channels 1 and 9, SSC was collected in channel 6 at a 785nm power of 2mW, DAPI was detected in channel 7 (450-505nm filter) at a 405nm laser power of 10mW, TbetZsgreen was detected in channel 2 (480-560nm filter) at a 488 laser power of 20mW, Foxp3 PE was detected in channel 3 (560-595 filter) at 561nm laser power of 200mW, and LE28 Cy5 were detected in channel 11 (660-745nm filter) and LAMP1 APC-Cy7 was detected in channel 12 (745-800nm filter) respectively, at a 642nm laser power of 150mW. Acquisition gates in INSPIRE were set as follows: a single cell gate was set on a Brightfield Area versus Brightfield Aspect Ratio plot to encompass single cells and eliminate debris and aggregates, a Brightfield Gradient RMS plot was used to gate single cells which were in focus, and gates were set in Raw Max Pixel plots to eliminate events saturating the camera in each fluorescent channel used. 20,000 single, focused, non-saturating events were acquired at 60X magnification, using the EDF element.

Data Analysis: Data analyses were performed in IDEAS 6.0 software (Amnis EMD-Millipore). A compensation matrix was created utilizing single color controls acquired with Brightfield and the 785 laser turned off, and all other lasers power set to the powers listed above. In IDEAS, single, focused, and nucleated (DAPI+) cells were gated and used for downstream analysis.

 Determination of Foxp3 in the nucleus: A series of masks was created which enabled the determination of the amount of Foxp3 in the nucleus. First, a tight mask was created on the nuclear image by eroding the default mask in one pixel (Erode (M07, 1). Next, a mask was created which identified Foxp3 staining (Intensity (M11, 11_Foxp3, 300-4095)). Lastly, a mask was created to identify pixels which contained DAPI staining and Foxp3 staining by combining the aforementioned masks with an AND operator ((Erode (M07, 1) AND Intensity (M11, 11_Foxp3, 300-4095)). The area of Foxp3 inside the nucleus was determined by creating an Area feature on the combined DAPI:Foxp3:AEP mask and gating the Area plot on DAPI+Foxp3+AEP+ cells.

Determination of Foxp3 and AEP co-localization in the nucleus: A series of masks was created which enabled the determination of the co-localization of Foxp3 and AEP in the nucleus. First, a mask was created which identified Foxp3 staining (Intensity (M03, 3_Foxp3, 300-4095)). Next, a mask was created which identified AEP staining (Intensity (M11, 11_Legumain/AEP, 362-4095)). The DAPI mask used is as described in the section above. Lastly, a mask was created to identify pixels which contained DAPI, Foxp3, and AEP staining by combining the aforementioned masks with an AND operator ((Erode (M07, 1) AND Intensity (M11, 11_Legumain/AEP, 362-4095)) AND (Erode (M07, 1) AND Intensity (M11, 11_Legumain, 60RPM for 16 hr. Wash and stain were performed on Affymetrix Fluidics Station 450 and scanned on Affymetrix GeneChip scanner 3000. Data were collected using Affymetrix AGCC software. Statistical and clustering analysis was performed with Partek Genomics Suite software using RMA normalization algorithm. Differentially expressed genes were identified with ANOVA analysis. Genes that are up- or downregulated more than 2 fold and with a p < 0.001 were considered significant.
Confocal Microscopy
Flow sorted iTregs, iTreg<sup>SPDL1</sup>, Tbet+iTreg and Tbet+iTreg<sup>SPDL1</sup> were first stained with AEP Cy5 followed by fixation and permeabilization. Cells were washed with permeabilization buffer and then stained with Foxp3 PE and DAPI. Images were acquired on a Leica SP8 point scanning confocal microscopy with white light super continuum lasers. Colocalization analysis were performed as previously described (Dunn et al., 2011). A comprehensive explanations of the confocal analysis is provided below:

Orthogonal projection view to enhance visualization of protein spatial location: An orthogonal projection of the image allows identification of the spatial location of a protein within the cell. It is a three-dimensional view of the cell but in a two-dimensional figure. A quadrant was drawn on a particular point in the nucleus, if all three fluorophores are present together in this 3D view, then the analysis shows this on merging the three images.

Deconvolution of the images to enhance signal to noise ratio in an orthogonal projection: Deconvolving is a recognized image processing technique to digitally reassign out of focus light to its originating focal plane. Deconvolution corrects optical aberration and provide higher resolution which enhances signal to noise ratio therefore minimizing false positive analysis. Combining deconvolution and orthogonal projection enhances understanding of the spatial location and co-localization of proteins within a cell.

Particle Analysis: Particle analysis was performed with the deconvolved images as recently shown (Kwon et al., 2017). Using this technique, we measured the number of Foxp3 and AEP particles within the nucleus. We next performed a quantitative analysis of the particles and plotted the values as follows: Each data point depicts the number of particles within the nucleus and the y axis denotes the relative volume of Foxp3 within the nucleus and similarly the relative volume of AEP within the nucleus. If cytosolic contamination occurs, it will be represented in this analysis as follows: 100% on y axis denotes that the entire particle is within the nucleus whereas 20% denotes a particle that does not explicitly localize in the nucleus.

We next quantitatively measured AEP and Foxp3 co-localization. Each data point depicts the number of particles within the nucleus that is colocalized and the y axis denotes the value which is the sum of the intensity of all voxels that colocalize with each other.

Foxp3 cleavage and Mass Spectrometry
Human Foxp3 protein and Tbet protein was purchased from Origene and then used in the cleavage assay in the presence of purified AEP protein (kindly provided by Dr. Colin Watts). Briefly, 1 μg of human AEP protein was incubated in 200 μL of activation buffer (0.1M NaCl, 0.1M NaOAc, pH 4.5) in 96 well round bottom plates for 30 mins at 37°C. In certain conditions, the AEP inhibitor was added (100 μM). Post AEP activation, either Foxp3 protein (5 μg) or Tbet protein (5 μg) was added to the wells with only activation buffer or activation buffer plus AEP or activation buffer plus AEP plus inhibitor. The plate was then incubated for 2 hr at 37°C. Samples were then reduced with LDS sample buffer and then subjected to immuno blotting. Once the proteins were run on a gel, they were transferred to a membrane and blotted for Foxp3 and Tbet. In separate experiments, gels were stained with Coomassie blue (Gel Code Blue reagent; Thermo Fisher Scientific) and then bands were cut out and subjected to mass spectrometry as previously described (Zhang et al., 2014). Briefly, bands were dehydrated using acetonitrile followed by vacuum centrifugation, reduced with 10 mM dithiothreitol and alkylated with 55 mM iodoacetamide. Gel pieces were then washed alternately with 25 mM ammonium bicarbonate followed by acetonitrile. Samples were digested with trypsin overnight at 37°C. Digested samples were analyzed by LC-MS/MS using an UltiMate<sup>®</sup> 3000 Rapid Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to an Orbitrap Elite (Thermo Fisher Scientific, Waltham, MA) mass spectrometer. Peptide mixtures were separated using a gradient from 92% A (0.1% FA in water) and 8% B (0.1% FA in acetonitrile) to 33% B, in 44 min at 300 nL min<sup>-1</sup>, using a 75 mm x 250 i.d. 1.7 mM C<sub>18</sub>, analytical column (Waters). Peptides were selected for fragmentation automatically by data dependent analysis. Data produced were searched using Mascot (Matrix Science UK), against the SWISSPROT database. Data were validated using Scaffold (Proteome Software, Portland, OR). Additional Foxp3 degradation experiments were performed with WT or mutated Foxp3 expressing 293 cells. The WT Foxp3 cDNA was isolated from a BamH1 + Xho1 digest of plasmid purchased from Addgene. The Mu Foxp3 containing alanine substituted for asparagine was synthesized by Integrated DNA Technologies custom gene synthesis service. The construct contain BamH1 and Xho1. These sites were used to clone both WT and mutant Foxp3 cDNAs into pC DNA3.1 and pEV Thy1.1 RV. The mutant Foxp3 construct also included a Not1 site to identify recombinant plasmids. The Foxp3 mutant cDNA was fully sequenced prior to use in experiments.

Pulse Chase Assays for Foxp3 protein turnover
Tbet+iTreg and Tbet<sup>SPDL1</sup> cells were washed and then aliquoted into 24 well tissue culture plates at 3x10<sup>6</sup>/ml. In certain experiments, WT or Aep<sup>−/−</sup> iTregs were plated into 24 well plates at 1x10<sup>6</sup>/ml. Cells were treated with cycloheximide (150 μg/ml) for the indicated time points and lysates were used to measure Foxp3 and Tbet protein degradation by immuno blotting. In order to block proteosomal degradation of Foxp3 and Tbet, MG132 (0.5 μM, Sigma-Aldrich) was added to certain culture conditions. AEP inhibitor MV026630 (100 μM, kindly provided by Prof. Colin Watts and Dr. Sander I. van Kasteren) was added to cultures to block specific AEP mediated degradation of Foxp3.

AEP and Foxp3 silencing and mutation assays
AEP specific shRNAs were obtained from Origene. On confirming efficient silencing of AEP in NIH 3T3 cells, the most efficient shRNA was chosen for further analysis. Single-stranded oligonucleotides containing shRNA targeted to AEP or scrambled sequence, 20 bp complementary to the sequence flanking a Xho1 site within with the expression vector pEV Thy1.1 RV (gift from Dr. Vanja Lazarevic, NCI, NIH), and a Not1 site were purchased from IDT and annealed in buffer containing 1 mM Tris pH 8.0, 50 mM NaCl
and 1 mM EDTA. The vector pEV Thy1.1 RV was digested with Xho1. The vector and the double stranded oligos were combined and a
Gibson reaction (New England Biolabs) was performed. Recombinant clones were identified by NotI restriction analysis. The integ-
rity of the insert sequence and orientation was confirmed by DNA sequencing. Silencing of AEP was further confirmed in 3T3 cells
and then was used to silencing AEP in primary murine Tbet+iTreg cells. pENTR Foxp3 was a gift from Prof. Anjana Rao [Addgene
plasmid # 16363 ([Wu et al., 2006]) containing WT human Foxp3 cDNA that was cloned into pEV-Thy1.1-RV using BglII and Xho1.
The AEP resistant human Foxp3 was synthesized as a mini-gene (IDT) and cloned into the BglII and Xho1 sites of pEV-Thy1.1-
RV. The N154A human Foxp3 mutant was created by inserting a 240 bp G-Block DNA fragment (IDT) between the Bcl1 and
BstB1 sites using the Gibson reaction (New England Biolabs). AEP cDNA was obtained from Prof. Colin Watts and cloned into
pEV-Thy1.1-RV using Xho1. For NLS experiments AEP NLS site was mutated whereby KRK was replaced to AAA at site 318-320.
pMIGR-mFoxp3 was a gift from Prof. Dan Littman (Addgene plasmid # 24067, unpublished). The N153A mutant was created by in-
serting a 182 bp G-Block DNA fragment (IDT) between the Bcl1 and BamH1 sites using the Gibson reaction (New England Biolabs).
All modified constructs were verified by sequencing before use.

Retroviral transductions of Tbet+iTreg cells were performed as follows. Briefly, cells were stimulated for 24 hr and then washed
once. Cells (0.5x10^6) were spin inoculated with 1ml of virus supernatant in the presence of polybrene (4 \mu g/ml) consisting of scramble
or AEP shRNA for 50 mins at 3000RPM. The cells were then placed at 37°C for 2 hr after which an additional 2ml of complete RPMI
media was added. Infection was monitored after 4 days as the percent of CD90.1 and AEP cy5 expression by flow cytometry.

CD90.1+Foxp3+Tbet+ iTreg cells were flow sorted and then adoptively transferred into a murine model of allogeneic GVHD and in vivo
stability of Foxp3 in Tbet+ iTreg cells was monitored.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical analysis was determined using GraphPad Prism 7 software. For experiments where two groups were compared, a two-
tailed Student’s t test was performed. For comparison of three or more groups, a one-way ANOVA was performed followed by
appropriate multiple comparison tests. For survival curve analysis, Kaplan-Meier survival curve analysis followed by a log rank
test was performed. Unless stated otherwise, histogram columns represent the mean values for each experiment and error bars
indicate the standard error of the mean. Data presented were considered significant if \( p \) value was $\leq 0.05$.

**DATA AND SOFTWARE AVAILABILITY**

The microarray data reported in this paper have been deposited in the NCBI Gene Expression Omnibus (GEO) database under
accession number GEO:GSE113815.